BioAge Labs
Biotechnology ResearchCalifornia, United States51-200 Employees
BioAge Labs is a clinical-stage biotechnology company focused on developing therapies for metabolic diseases by targeting the biology of human aging. Its lead candidate, BGE-102, is an oral, brain-penetrant NLRP3 inhibitor aimed at reducing cardiovascular risk and treating retinal diseases; a Phase 1 SAD/MAD study is underway with topline data and additional MAD cohorts anticipated in the first half of 2026. The company is also pursuing obesity-focused programs, including long-acting injectable and oral APJ agonists, supported by preclinical programs that leverage a longevity-informed discovery platform. Based in Emeryville, California, BioAge operates within the biotechnology research sector, pursuing early clinical development alongside its discovery efforts. The organization offers a comprehensive benefits package for employees, including health coverage, childcare and fertility support, and a 401(k) with employer contributions, along with a commitment to training and professional development. In 2026, leadership changes were reported involving the CEO role.
1-888-653-2347 
support@leadiq.com 
